Legal Representation
Attorney
Caroline Duncan
USPTO Deadlines
Next Deadline
158 days remaining
NOA E-Mailed - SOU Required
Due Date
July 09, 2026
Extension Available
Until January 09, 2027
Application History
47 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jan 9, 2026 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 8, 2026 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Jan 8, 2026 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Jan 8, 2026 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jan 5, 2026 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | Loading... |
| Jan 5, 2026 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Jan 5, 2026 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Jan 5, 2026 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Jul 10, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jul 9, 2025 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Jul 9, 2025 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Jul 9, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 4, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 9, 2025 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jan 9, 2025 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jan 9, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jul 9, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| May 14, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| May 14, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Apr 24, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Apr 9, 2024 | EXPT | T | EXPARTE APPEAL TERMINATED | Loading... |
| Apr 9, 2024 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Mar 12, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Mar 12, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Mar 12, 2024 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Oct 24, 2023 | ERFR | I | TEAS REQUEST FOR RECONSIDERATION RECEIVED | Loading... |
| Oct 24, 2023 | EXPI | T | EX PARTE APPEAL-INSTITUTED | Loading... |
| Oct 24, 2023 | JURT | T | JURISDICTION RESTORED TO EXAMINING ATTORNEY | Loading... |
| Oct 24, 2023 | EXAF | T | EXPARTE APPEAL RECEIVED AT TTAB | Loading... |
| Sep 27, 2023 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED | Loading... |
| Sep 27, 2023 | GNFR | O | FINAL REFUSAL E-MAILED | Loading... |
| Sep 27, 2023 | CNFR | R | FINAL REFUSAL WRITTEN | Loading... |
| Aug 17, 2023 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Aug 16, 2023 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Aug 16, 2023 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| May 16, 2023 | XELG | O | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | Loading... |
| May 16, 2023 | XELR | I | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | Loading... |
| Feb 16, 2023 | GPRN | O | NOTIFICATION OF PRIORITY ACTION E-MAILED | Loading... |
| Feb 16, 2023 | GPRA | O | PRIORITY ACTION E-MAILED | Loading... |
| Feb 16, 2023 | CPRA | R | PRIORITY ACTION WRITTEN | Loading... |
| Jan 19, 2023 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Jan 19, 2023 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 19, 2023 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Jan 19, 2023 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Jan 18, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Nov 30, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Nov 14, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
A full line of pharmaceuticals for the treatment of depression, hypertension, malaria, metastatic prostate cancer, benign prostatic hyperplasia, partial seizures in adults with epilepsy, attention deficit hyperactivity disorder (ADHD), heart failure in adults, heart failure in pediatric patients, atrial fibrillation in adults, edema associated with congestive heart failure, edema associated with cirrhosis of the liver, edema associated with nephrotic syndrome, steroid-induced edema, idiopathic edema, edema due to secondary hyperaldosteronism, acute enterocolitis, duodenal ulcer, and irritable bowel syndrome being irritable colon, spastic colon, mucous colitis; anti-inflammatory medicines and immunosuppressive agents, namely, corticosteroids; pharmaceutical preparations for the treatment of cancers and abnormal cells; all of the foregoing excluding pharmaceutical preparations acting on the peripheral or central nervous system, surgical kits comprised of medical and surgical apparatus and instruments, and surgical implants comprised of human and animal tissue; all of the foregoing excluding anti-infective pharmaceutical preparations
Class 010
Medical devices, namely, lasers and fibre-optic wires and cables for use in photodynamic therapy with the administration of a photosensitizing agent for the treatment of cancer
Classification
International Classes
005
010